Tuesday, October 4, 2022


Biotechnology News Magazine

GreenLight Biosciences to Work with Fraunhofer IME

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

March 29, 2021

GreenLight Biosciences will work with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME to research new and promising RNA-based advances for environmentally-friendly food production for a growing global population.

While crop protection uses a different type of RNA from Covid vaccines, GreenLight’s proprietary platform allows for the large-scale production of RNA for human health, animal health, and plant health. The collaboration with Fraunhofer IME aims to help GreenLight Biosciences create advances that protect crops around the world while ensuring biodiversity.

Fraunhofer IME will provide access to scientific experts and state-of-the-art laboratory resources to boost GreenLight Biosciences’ research and development capabilities. Founded in 1949 to advance the commercial application of basic science, Fraunhofer is known for a wide range of innovations with global impact, ranging from the MP3 standard for music compression to solar panels of world record-breaking efficiency.

GreenLight Biosciences is developing new crop protections that draw on scientific advances underpinning large-scale production of RNA Covid vaccines. These solutions will enable farmers to grow crops without harming beneficial insects like bees while being safe for people, soil, and water. RNA-based products only target the insect that they are designed to control and break down rapidly.

This collaborative effort will focus on identifying new sustainable RNA alternatives to petroleum-based chemical pesticides. Among the first products to be trialled will be GreenLight’s RNA solution to protect potatoes from the Colorado Potato Beetle.

Fraunhofer IME offers advanced biological assays and bioinformatic tools that can be used to quickly identify pest targets, develop new bioactive molecules, and validate their efficacy on crops. The research will be conducted in Giessen, Germany.

“RNA biologics is an exciting field that holds great potential for allowing farmers to deliver sustainable, environmentally-safe products to give consumers the cleaner, greener products they demand,” said Prof. Dr. Andreas Vilcinskas, who heads the branch for bioresources at Fraunhofer IME. “We are teaming up with GreenLight Biosciences to help the world gain greater food security with more sustainable and eco-friendly agriculture.”

“Finding ways to farm without harming bees and without damaging biodiversity is one of humanity’s biggest challenges,” said Dr. Andrey Zarur, CEO of GreenLight Biosciences. “To tackle this we are joining forces with one of the world’s most experienced research institutes in a country long-dedicated to sustainable agriculture.”


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine